• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on Paychex Inc. and Pfizer Inc.

    3/28/24 5:28:00 PM ET
    $PAYX
    $PFE
    Diversified Commercial Services
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PAYX alert in real time by email

    TROY, Mich., March 28, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Paychex Inc. (NYSE:PAYX) as its "Stock to Study" and Pfizer Inc. (NYSE:PFE) as its "Undervalued Stock" in the June/July 2024 issue for investors' informational and educational use.

    "One of the top stock market stories of the week is the Reddit IPO. While IPOs are always headline-grabbing," said Ken Zendel, chief executive officer of the National Association of Investors Inc., publisher of BetterInvesting, "the BetterInvesting educators remind investors to focus on the fundamentals, such as earnings, of individual companies, whether by using the Stock Selection Guide® or by doing their homework via other methods."

    Learn more about how to analyze companies and pick the best stocks at:

    https://www.betterinvesting.org/learn-about-investing/investor-education/getting-started-with-stocks/how-to-pick-great-stocks

    Check the June/July 2024 issue of BetterInvesting Magazine for more details about the latest stocks. Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of Paychex Inc. and Pfizer Inc. by viewing their fundamental data and applying judgments.

    Committee members are Lauren Adams, CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.  Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-paychex-inc-and-pfizer-inc-302103142.html

    SOURCE NAIC-BetterInvesting

    Get the next $PAYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAYX
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Paychex Inc.
    $PAYX
    1/27/2026$98.00Underweight
    Cantor Fitzgerald
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Paychex Inc.
    $PAYX
    12/9/2025$140.00 → $121.00Market Perform
    BMO Capital Markets
    Pfizer Inc.
    $PFE
    12/2/2025$26.00Neutral
    Citigroup
    Pfizer Inc.
    $PFE
    11/13/2025$30.00Sector Outperform
    Scotiabank
    Paychex Inc.
    $PAYX
    10/23/2025$139.00Neutral
    Citigroup
    More analyst ratings

    $PAYX
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAYX
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    2/17/26 5:18:05 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bonadio Tom bought $98,498 worth of shares (1,000 units at $98.50), increasing direct ownership by 5% to 21,504 units (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:03 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Director Doody Joseph bought $98,760 worth of Common Stock - Family Trust (1,000 units at $98.76) (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:05 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $PAYX
    $PFE
    SEC Filings

    View All

    SEC Form 13F-HR filed by Pfizer Inc.

    13F-HR - PFIZER INC (0000078003) (Filer)

    2/12/26 4:22:51 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PFIZER INC (0000078003) (Filer)

    2/3/26 7:01:37 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Paychex Inc.

    SCHEDULE 13G/A - PAYCHEX INC (0000723531) (Subject)

    1/30/26 2:19:28 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $PAYX
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Paychex with a new price target

    Cantor Fitzgerald initiated coverage of Paychex with a rating of Underweight and set a new price target of $98.00

    1/27/26 8:48:32 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $PAYX
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonadio Tom bought $98,498 worth of shares (1,000 units at $98.50), increasing direct ownership by 5% to 21,504 units (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:03 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Director Doody Joseph bought $98,760 worth of Common Stock - Family Trust (1,000 units at $98.76) (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:05 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAYX
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM

    Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those continuing on daily oral therapy ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced final data from the LATITUDE phase III trial, confirming its long-acting injectable treatment for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of antiretroviral treatment (ART) adherence challenges.1 The 4

    2/18/26 5:00:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

    The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036,

    2/17/26 5:31:00 PM ET
    $ABBV
    $BMY
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAYX
    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Paychex Announces $1 Billion Stock Repurchase Authorization and Declares Quarterly Dividend

    Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management ("HCM") company, today announced that its Board of Directors has authorized the purchase of up to $1 billion of the Company's common stock. The new authorization replaces the prior 2024 authorization to repurchase $400 million of the Company's common stock. In addition, the Board has declared a regular quarterly cash dividend on Paychex common stock of $1.08 per share, payable on February 27, 2026, to shareholders of record as of January 28, 2026. "For many years, we have maintained a long-standing commitment to delivering outstanding value to our investors," said John Gibson, Paychex President and CEO. "Today's n

    1/16/26 9:15:00 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. Abou

    1/5/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAYX
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Paychex Inc.

    SC 13G/A - PAYCHEX INC (0000723531) (Subject)

    11/13/24 10:27:58 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    SEC Form SC 13G filed by Paychex Inc.

    SC 13G - PAYCHEX INC (0000723531) (Subject)

    2/9/24 6:05:54 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    SEC Form SC 13G filed by Paychex Inc.

    SC 13G - PAYCHEX INC (0000723531) (Subject)

    1/25/24 3:33:12 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $PAYX
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Paychex Expands Board of Directors, Appoints New Member

    Experienced executive, J. Michael Hansen, appointed to Paychex Board of Directors Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management (HCM) company, announced today that the company's Board of Directors has voted to expand to 11 members from 10 members. The Board has also appointed J. Michael Hansen to fill the new position as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119850035/en/ Mr. Hansen brings deep financial expertise, having served as Executive Vice President & Chief Financial Officer (CFO) of Cintas Corporation (NASDAQ:CTAS) for more than 10 years. Upon his retirem

    1/20/26 8:30:00 AM ET
    $CTAS
    $PAYX
    Garments and Clothing
    Industrials
    Diversified Commercial Services

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Paychex and PayPal Team Up to Bring Direct Deposit Alternatives Into Paychex Flex® Perks

    Paychex Flex Perks expands to 25 employee benefit offerings with PayPal integration Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management (HCM) company, announced today a new partnership with PayPal (NASDAQ:PYPL) within its Paychex Flex® Perks platform, Paychex's digital marketplace of curated employee benefits. Through this collaboration, employees of Paychex customers have the ability to easily set up PayPal Direct Deposit, providing up to two-day early access to their paychecks. According to the Federal Deposit Insurance Corporation, approximately 5.6 million U.S. households were unbanked in 2023 where no one in the household owned a checking or savings account at

    1/8/26 9:00:00 AM ET
    $PAYX
    $PYPL
    Diversified Commercial Services
    Industrials